Key points from article :
A groundbreaking new brain scanning technology developed in Scotland may soon transform how doctors monitor glioblastoma, the most aggressive type of brain tumour. Each year, over 3,000 people in the UK are diagnosed with this deadly cancer, with half dying within 15 months despite intensive treatment. Now, researchers at the University of Aberdeen and NHS Grampian—led by Professor Anne Kiltie—have received £350,000 in Scottish Government funding to trial a world-first imaging tool called Field Cycling Imaging (FCI), a new form of low-field MRI that produces more detailed, dynamic scans of the brain.
FCI, which builds on MRI technology first invented in Aberdeen 50 years ago, allows scientists to vary the magnetic field strength during a single scan. This offers an unprecedented level of tissue information, without the need for contrast dye, which can cause complications for some patients. Unlike standard MRI, FCI could distinguish between true tumour progression and "pseudo-progression"—tissue changes that mimic cancer growth but are not malignant. This breakthrough could ensure patients receive the most appropriate treatment without unnecessary changes or interruptions.
The upcoming study will focus on patients undergoing chemotherapy after initial surgery and chemoradiotherapy. By detecting real tumour progression earlier, clinicians may be able to switch to more effective therapies sooner. Conversely, identifying pseudo-progression could prevent premature discontinuation of helpful treatments. This would not only improve survival outcomes, but also reduce patient anxiety and healthcare costs by avoiding misdiagnosis.
The initiative has been praised by cancer organisations such as Friends of ANCHOR and The Brain Tumour Charity, which see it as a critical step in improving care for those affected by glioblastoma. If successful, this pioneering approach could mark a major shift in brain cancer treatment in the UK and beyond.
